Meet Resistell in Davos on 21.10.2021 at the 4th Swiss Symposium in Point-of-Care Diagnostics

Resistell - The EPFL spin-off knows how to find the right medication around 100 times faster. This can significantly increase a patient's chance of survival.

In their development, start-ups face an important challenge: the creation of a prototype. A crucial step, where many risks have to be overcome and where different skills have to be combined.

Swiss Biotech startups are considered among the most promising and innovative companies in the world. Big industry players have already acquired many Biotech startups and large transactions had a relevant impact on the entire Swiss ecosystem. Discover now 10 Swiss Biotech startups to watch in 2020. The practice of medicine has changed dramatically over the past years and we all know that the healthcare systems are becoming more complex and more expensive. Much of that progress is likely to result from advances in personalized medicine. This new treatment paradigm aims to ensure that patients get the therapies best suited to their specific genetic conditions.

Resistell AG has today closed an oversubscribed series A financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test.

The future of antibiotics depends on all of us! Each November, World Antibiotic Awareness Week (WAAW) aims to increase global awareness of antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.